For the past several months, you likely haven’t read or seen much about the opioid crisis. All of the information about the opioid crisis that once flooded your inboxes and social media feeds has seemingly been replaced with news related to the COVID-19 pandemic. While it can sometimes be said that no news is good […] Continue
On July 16th, the FDA approved Orphengesic Forte, a non-opioid combination analgesic for the treatment of mild to moderate pain associated with acute musculoskeletal conditions. The FDA’s approval came earlier than expected, which many have viewed as a reinforcement of the FDA’s commitment to do everything in its power to combat the opioid epidemic. Orphengesic […] Continue
Patients with chronic pain often present a challenging treatment scenario for health care practitioners. This has historically been the case, and the opioid crisis has served to create additional challenges by discouraging the use of opioids which have traditionally been the mainstays of pain therapy. Because of the opioid epidemic, treatment guidelines have emerged which […] Continue
The FDA has approved the first ibuprofen-acetaminophen combination product, which will be available as an over-the-counter product and marketed under the name of Advil Dual Action. The use of Advil Dual Action is approved for the temporary relief of minor aches and pains due to headache, toothache, backache, menstrual cramps, muscular aches and minor pain […] Continue
The COVID-19 pandemic has provoked a variety of responses from the federal government in addition to nearly every state government. On January 31, 2020, the Secretary of HHS declared a public health emergency due to COVID-19. In turn, this declaration prompted the DEA to identify steps it could take to ensure the public’s continued access […] Continue